Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant murine interleukin-1 alpha
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal, Intravenous
01
Overview
Recombinant murine interleukin-1 alpha (rMuIL-1 alpha) is a laboratory-produced version of the mouse IL-1α cytokine. It acts as a potent mediator of the inflammatory response by binding to and activating the interleukin-1 receptor (IL-1R). Preclinical studies in murine models have demonstrated its potential to inhibit tumor growth, particularly in B16 melanoma models when used alone or synergistically with interferon-alpha. Additionally, it enhances host defense against bacterial infections, such as *Listeria monocytogenes*, by promoting the recruitment of neutrophils and macrophages to the site of infection. While a critical tool in immunology research, this specific murine protein is not used in human clinical medicine.
- Other names
- murine interleukin-1 alphamouse IL-1 alpharecombinant mouse interleukin-1 alpha
02
Targets
IL1R2 (Interleukin-1 receptor type II)IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on recombinant murine interleukin-1 alpha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant murine interleukin-1 alpha.